Atropine reinstates inflammation-induced dysregulation of dopamine and its receptors in human scleral cells: Implications for myopia therapy
Indian Journal of Ophthalmology · 2026
DOI: 10.4103/ijo.ijo_2901_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Ophthalmology, 2026. Verfasst von Shivapriya Shivakumar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Grow Research Laboratory, Narayana Netralaya Foundation, Bangalore, Karnataka. Hauptthemen laut MEDLINE: Myopia, Atropine, Sclera, Dopamine. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
Myopia is a complex refractive disorder and a leading cause of visual impairment worldwide. Inflammation plays a crucial role in the onset and progression of myopia. This study aimed to investigate the role of atropine in modulating inflammation-induced alterations in dopamine and its receptors in primary human scleral cells under in vitro experimental conditions.
Methods
Human primary scleral cells were exposed to long-term inflammatory conditions in the presence or absence of atropine or dopamine hydrochloride. Following treatment, gene and protein expressions were analyzed for inflammatory markers, dopamine receptors, and extracellular matrix (ECM) using quantitative polymerase chain reaction, immunoblotting, and immunofluorescence. Secretory cytokines and dopamine levels were measured using an automated enzyme-linked immunosorbent assay system.
Results
In primary human scleral cells, atropine treatment increases the dopamine receptor expression. Prolonged inflammatory stimulation led to a marked reduction in dopamine and its receptor (D1–D2) expression, which was effectively restored following atropine treatment in scleral cells. Under inflammatory conditions, atropine significantly suppressed pro-inflammatory cytokines expression at both the transcript and protein levels and mitigated the inflammation-induced dysregulation of ECM genes.
Conclusion
Our findings demonstrate atropine restores inflammation-induced dopaminergic and extracellular matrix dysregulation in human scleral cells, highlighting its dual anti-inflammatory and neuro-modulatory roles. The restoration of dopamine signaling and ECM balance underscores atropine’s potential as a therapeutic agent for myopia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Grow Research Laboratory, Narayana Netralaya Foundation, Bangalore, Karnataka.
- Faculty of Medicine and Life sciences, School of Mental Health and Neurosciences, Maastricht University, Maastricht, Netherlands.
- Department of Cornea and Refractive Surgery, Narayana Nethralaya Eye Hospital, Bangalore, Karnatake, India.
Zitieren
APA
Shivakumar, S., Kiran, N., Shetty, R., Krishnamurthy, P. H., Ghosh, A., Deshpande, V., & Jeyabalan, N. (2026). Atropine reinstates inflammation-induced dysregulation of dopamine and its receptors in human scleral cells: Implications for myopia therapy. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_2901_25
Vancouver
Shivakumar S, Kiran N, Shetty R, Krishnamurthy PH, Ghosh A, Deshpande V, et al. Atropine reinstates inflammation-induced dysregulation of dopamine and its receptors in human scleral cells: Implications for myopia therapy. Indian Journal of Ophthalmology. 2026. doi:10.4103/ijo.ijo_2901_25
BibTeX
@article{Shivakumar2026,
author = {Shivakumar, Shivapriya and Kiran, Nithin and Shetty, Rohit and Krishnamurthy, Pradhyumna Hulsermane and Ghosh, Arkasubhra and Deshpande, Vrushali and Jeyabalan, Nallathambi},
title = {Atropine reinstates inflammation-induced dysregulation of dopamine and its receptors in human scleral cells: Implications for myopia therapy},
journal = {Indian Journal of Ophthalmology},
year = {2026},
doi = {10.4103/ijo.ijo_2901_25}
}
EUVIMED